Abstract
Background: Genetic events cannot account for the complexity of human carcinogenesis alone. Mutations of epigenetic regulators and aberrations of their expression patterns have been detected in various human malignancies. Methylation of histone H3 at lysine 4 (H3K4me), is an evolutionarily conserved histone modification that marks regions of active transcription and regulates cell growth, migration, and invasion. The MLL/KMT2 family of histone methyltransferases specifically methylate histone H3 at lysine 4.
Objective: The aim of this study was to explore the role of KMT2C/MLL3 as well as key histone modification activating markers, such as H3K4me2 and H3K4me3 in a cohort of surgically resected human lung adenocarcinomas in an effort to reveal possible biomarkers for lung adenocarcinoma diagnosis and prognosis and potential therapeutic targets.
Method: The immunohistochemical expression of KMT2C/MLL3, H3K4me2 and H3K4me3 was analyzed in formalin fixed paraffin embedded tissue from 96 patients with lung adenocarcinoma. Results were associated with clinicopathologic parameters and patient’s prognosis.
Results: Nuclear expression of KMT2C/MLL3 in epithelial cells was independently associated with shorter overall survival. Cytoplasmic H3K4me2 expression was associated withT stage and nuclear H3K4me2 expression was associated with female gender and patients’ prognosis. The latter association persisted after multivariate analysis. No association was found between H3K4me3 expression and clinicopathological data or disease outcome in our cohort of patients.
Conclusion: These results suggest that the pattern of histone modifications and KMT2C/MLL3 expression can be used as an independent prognostic factor in lung adenocarcinoma, revealing that chromatin remodeling is criticallyinvolved in cancer progression.
Keywords: Lung adenocarcinoma, histone 3 lysine 4 methylation, H3K4me2, H3K4me3 histome methyltransferase, KMT2C/MLL3, prognosis.
Graphical Abstract
Current Molecular Pharmacology
Title:H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Volume: 14
Author(s): Pinelopi Bosgana, Sophia Nikou, Foteinos-Ioannis Dimitrakopoulos, Souzana Logotheti, Vasiliki Tzelepi, Charalambos Kalophonos, Vasiliki Bravou, Eleni Kourea, Fotios Sampsonas*Vassiliki Zolota*
Affiliation:
- Department of Pulmonology, Medical School, University of Patras, Patras,Greece
- Department of Pathology, Medical School, University of Patras, Patras,Greece
Keywords: Lung adenocarcinoma, histone 3 lysine 4 methylation, H3K4me2, H3K4me3 histome methyltransferase, KMT2C/MLL3, prognosis.
Abstract: Background: Genetic events cannot account for the complexity of human carcinogenesis alone. Mutations of epigenetic regulators and aberrations of their expression patterns have been detected in various human malignancies. Methylation of histone H3 at lysine 4 (H3K4me), is an evolutionarily conserved histone modification that marks regions of active transcription and regulates cell growth, migration, and invasion. The MLL/KMT2 family of histone methyltransferases specifically methylate histone H3 at lysine 4.
Objective: The aim of this study was to explore the role of KMT2C/MLL3 as well as key histone modification activating markers, such as H3K4me2 and H3K4me3 in a cohort of surgically resected human lung adenocarcinomas in an effort to reveal possible biomarkers for lung adenocarcinoma diagnosis and prognosis and potential therapeutic targets.
Method: The immunohistochemical expression of KMT2C/MLL3, H3K4me2 and H3K4me3 was analyzed in formalin fixed paraffin embedded tissue from 96 patients with lung adenocarcinoma. Results were associated with clinicopathologic parameters and patient’s prognosis.
Results: Nuclear expression of KMT2C/MLL3 in epithelial cells was independently associated with shorter overall survival. Cytoplasmic H3K4me2 expression was associated withT stage and nuclear H3K4me2 expression was associated with female gender and patients’ prognosis. The latter association persisted after multivariate analysis. No association was found between H3K4me3 expression and clinicopathological data or disease outcome in our cohort of patients.
Conclusion: These results suggest that the pattern of histone modifications and KMT2C/MLL3 expression can be used as an independent prognostic factor in lung adenocarcinoma, revealing that chromatin remodeling is criticallyinvolved in cancer progression.
Export Options
About this article
Cite this article as:
Bosgana Pinelopi , Nikou Sophia , Dimitrakopoulos Foteinos-Ioannis , Logotheti Souzana , Tzelepi Vasiliki , Kalophonos Charalambos , Bravou Vasiliki , Kourea Eleni , Sampsonas Fotios *, Zolota Vassiliki *, H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma, Current Molecular Pharmacology 2021; 14 (6) : e301221185417 . https://dx.doi.org/10.2174/1874467213999200831130739
DOI https://dx.doi.org/10.2174/1874467213999200831130739 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Protein Kinase C Modulates Aurora-kinase Inhibition Induced by CCT129202 in HMC-1560,816 Cell Line
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Modifications: New Therapeutic Targets in Primary Myelofibrosis
Current Stem Cell Research & Therapy DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Hematological Targets of Radiation Damage
Current Drug Targets The LPS-Pretreated MSCs Supply a Positive Microenvironment for Tumor Cell Proliferation and Clone Formation
Current Protein & Peptide Science P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells
Current Pharmaceutical Design Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry